Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Psoriasis AND cardiovascular risk AND anti-TNF therapy:

Search results

Items: 1 to 20 of 26

1.

Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.

Caiazzo G, Fabbrocini G, Di Caprio R, Raimondo A, Scala E, Balato N, Balato A.

Front Immunol. 2018 Aug 13;9:1668. doi: 10.3389/fimmu.2018.01668. eCollection 2018. Review.

2.

Effect of anti-rheumatic treatment on selenium levels in inflammatory arthritis.

Deyab G, Hokstad I, Aaseth J, Småstuen MC, Whist JE, Agewall S, Lyberg T, Tveiten D, Hjeltnes G, Zibara K, Hollan I.

J Trace Elem Med Biol. 2018 Sep;49:91-97. doi: 10.1016/j.jtemb.2018.05.001. Epub 2018 May 3.

PMID:
29895378
3.
4.

Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Deyab G, Hokstad I, Whist JE, Småstuen MC, Agewall S, Lyberg T, Bottazzi B, Meroni PL, Leone R, Hjeltnes G, Hollan I.

PLoS One. 2017 Feb 22;12(2):e0169830. doi: 10.1371/journal.pone.0169830. eCollection 2017.

5.

Changes in Body Mass Index and Lipid Profile in Psoriatic Patients After Treatment With Standard Protocol of Infliximab.

Ehsani AH, Mortazavi H, Balighi K, Hosseini MS, Azizpour A, Hejazi SP, Goodarzi A, Darvari SB.

Acta Med Iran. 2016 Sep;54(9):570-575.

6.

Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study.

Pina T, Corrales A, Lopez-Mejias R, Armesto S, Gonzalez-Lopez MA, Gómez-Acebo I, Ubilla B, Remuzgo-Martínez S, Gonzalez-Vela MC, Blanco R, Hernández JL, Llorca J, Gonzalez-Gay MA.

J Dermatol. 2016 Nov;43(11):1267-1272. doi: 10.1111/1346-8138.13398. Epub 2016 Apr 7.

PMID:
27062420
7.

Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis.

Piaserico S, Osto E, Famoso G, Zanetti I, Gregori D, Poretto A, Iliceto S, Peserico A, Tona F.

Atherosclerosis. 2016 Aug;251:25-30. doi: 10.1016/j.atherosclerosis.2016.05.036. Epub 2016 May 21.

PMID:
27236353
8.

Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.

Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-Randone S, Matucci-Cerinic M, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, Goletti D; Italian board for the TAilored BIOlogic therapy (ITABIO).

Semin Arthritis Rheum. 2016 Apr;45(5):519-32. doi: 10.1016/j.semarthrit.2015.10.001. Epub 2015 Oct 22. Review.

PMID:
26607440
9.

Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.

Atzeni F, Costa L, Caso F, Scarpa R, Sarzi-Puttini P.

J Rheumatol Suppl. 2015 Nov;93:79-81. doi: 10.3899/jrheum.150643. Review.

PMID:
26523064
10.

Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti-Tumor Necrosis Factor Agents During Pregnancy.

Bröms G, Granath F, Ekbom A, Hellgren K, Pedersen L, Sørensen HT, Stephansson O, Kieler H.

Clin Gastroenterol Hepatol. 2016 Feb;14(2):234-41.e1-5. doi: 10.1016/j.cgh.2015.08.039. Epub 2015 Sep 12.

PMID:
26375613
11.

Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate-to-severe psoriasis undergoing anti-tumor necrosis factor-α therapy.

Pina T, Genre F, Lopez-Mejias R, Armesto S, Ubilla B, Mijares V, Dierssen-Sotos T, Corrales A, Gonzalez-Lopez MA, Gonzalez-Vela MC, Blanco R, Hernández JL, Llorca J, Gonzalez-Gay MA.

J Dermatol. 2016 Apr;43(4):389-94. doi: 10.1111/1346-8138.13094. Epub 2015 Sep 14.

PMID:
26364678
12.

Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy.

Pina T, Genre F, Lopez-Mejias R, Armesto S, Ubilla B, Mijares V, Dierssen-Sotos T, Gonzalez-Lopez MA, Gonzalez-Vela MC, Blanco R, Hernández JL, Llorca J, Gonzalez-Gay MA.

J Eur Acad Dermatol Venereol. 2015 Oct;29(10):1995-2001. doi: 10.1111/jdv.13131. Epub 2015 Mar 30.

PMID:
25823684
13.

Anti-TNFtherapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study.

Pina T, Genre F, Lopez-Mejias R, Armesto S, Ubilla B, Mijares V, Dierssen-Sotos T, Corrales A, Gonzalez-Lopez MA, Gonzalez-Vela MC, Blanco R, Llorca J, Gonzalez-Gay MA.

J Eur Acad Dermatol Venereol. 2016 Jan;30(1):92-5. doi: 10.1111/jdv.13005. Epub 2015 Feb 4.

PMID:
25650695
14.

Anti-TNFtherapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study.

Pina T, Armesto S, Lopez-Mejias R, Genre F, Ubilla B, Gonzalez-Lopez MA, Gonzalez-Vela MC, Corrales A, Blanco R, Garcia-Unzueta MT, Hernandez JL, Llorca J, Gonzalez-Gay MA.

J Eur Acad Dermatol Venereol. 2015 Jul;29(7):1325-30. doi: 10.1111/jdv.12814. Epub 2014 Oct 29.

PMID:
25353352
15.

Effects of anti-TNF-α agents on circulating endothelial-derived and platelet-derived microparticles in psoriasis.

Pelletier F, Garnache-Ottou F, Biichlé S, Vivot A, Humbert P, Saas P, Seillès E, Aubin F.

Exp Dermatol. 2014 Dec;23(12):924-5. doi: 10.1111/exd.12551.

PMID:
25255926
16.

Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis.

Favarato MH, Mease P, Gonçalves CR, Gonçalves Saad C, Sampaio-Barros PD, Goldenstein-Schainberg C.

Clin Exp Rheumatol. 2014 Mar-Apr;32(2):182-7. Epub 2014 Jan 30.

PMID:
24480317
17.

Psoriasis and cardiovascular disorders.

Ryan C, Menter A.

G Ital Dermatol Venereol. 2012 Apr;147(2):179-87. Review.

PMID:
22481581
18.

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.

Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A.

JAMA. 2011 Aug 24;306(8):864-71. doi: 10.1001/jama.2011.1211.

PMID:
21862748
19.

Metabolic comorbidities and psoriasis.

Gisondi P, Ferrazzi A, Girolomoni G.

Acta Dermatovenerol Croat. 2010;18(4):297-304. Review.

PMID:
21251450
20.

Anti-tumor necrosis factor-α therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients.

Mazzoccoli G, Notarsanto I, de Pinto GD, Dagostino MP, De Cata A, D'Alessandro G, Tarquini R, Vendemiale G.

Intern Emerg Med. 2010 Dec;5(6):495-500. doi: 10.1007/s11739-010-0458-6. Epub 2010 Sep 16. Erratum in: Intern Emerg Med. 2011 Feb;6(1):97.

PMID:
20845087

Supplemental Content

Loading ...
Support Center